News

New analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart failure, with differences seen within 30 days and sustained through 30…

People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in the field of vision, according…

The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy…

Many adverse-event reports and safety signals linked to Amvuttra (vutrisiran) treatment for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in real-world databases were consistent…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for transthyretin…

Treatment with Wainua (eplontersen) was associated with slower disease progression and improved quality of life in both men and women with hereditary transthyretin…

A blood test measuring levels of the protein MR-proADM may help predict heart failure events (worsening of symptoms requiring immediate medical care) and death in…

Carpal tunnel syndrome (CTS) in both wrists may be a red flag of transthyretin amyloidosis (ATTR), including hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a…

Starting Attruby (acoramidis) early and taking it continuously helps adults with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer, stay out of the hospital for…

Amvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability, and improves quality of life in East Asian adults with hereditary transthyretin amyloidosis with polyneuropathy…